Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.

Prognosis of Philadelphia-positive (Ph(+)) acute lymphoblastic leukemia (ALL) in the elderly has improved during the imatinib era. We investigated dasatinib, another potent tyrosine kinase inhibitor, in combination with low-intensity chemotherapy. Patients older than age 55 years were included in the European Working Group on Adult ALL (EWALL) study number 01 for Ph(+) ALL (EWALL-PH-01 international study) and were treated with dasatinib 140 mg/day (100 mg/day over 70 years) with intrathecal chemotherapy, vincristine, and dexamethasone during induction. Patients in complete remission continued consolidation with dasatinib, sequentially with cytarabine, asparaginase, and methotrexate for 6 months. Maintenance therapy was dasatinib and vincristine/dexamethasone reinductions for 18 months followed by dasatinib until relapse or death. Seventy-one patients with a median age of 69 years were enrolled; 77% had a high comorbidity score. Complete remission rate was 96% and 65% of patients achieved a 3-log reduction in BCR-ABL1 transcript levels during consolidation. Only 7 patients underwent allogeneic hematopoietic stem cell transplantation. At 5 years, overall survival was 36% and up to 45% taking into account deaths unrelated to disease or treatment as competitors. Thirty-six patients relapsed, 24 were tested for mutation by Sanger sequencing, and 75% were T315I-positive. BCR-ABL1(T315I) was tested by allele-specific oligonucleotide reverse transcription-quantitative polymerase chain reaction in 43 patients and detection was associated with short-term relapses. Ten patients (23%) were positive before any therapy and 8 relapsed, all with this mutation. In conclusion, dasatinib combined with low-intensity chemotherapy was well-tolerated and gave long-term survival in 36% of elderly patients with Ph(+) ALL. Monitoring of BCR-ABL1(T315I) from diagnosis identified patients with at high risk of early relapse and may help to personalize therapy.

[1]  C. Bloomfield,et al.  Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665 , 2016, Leukemia & lymphoma.

[2]  X. Thomas,et al.  Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia , 2016, Drug design, development and therapy.

[3]  L. Escoda,et al.  Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. , 2016, Leukemia research.

[4]  Z. Estrov,et al.  Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia , 2015, Cancer.

[5]  M. Konopleva,et al.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. , 2015, The Lancet. Oncology.

[6]  H. Kantarjian,et al.  Monoclonal antibodies in acute lymphoblastic leukemia. , 2015, Blood.

[7]  J. Cayuela,et al.  Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. , 2015, Blood.

[8]  T. Brümmendorf,et al.  Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. , 2014, Blood.

[9]  H. Kantarjian,et al.  Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia , 2014, American journal of hematology.

[10]  H. Kantarjian,et al.  Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. , 2014, American journal of hematology.

[11]  Z. Estrov,et al.  Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. , 2013, Blood.

[12]  J. Cortes,et al.  Dasatinib for the treatment of Philadelphia chromosome-positive leukemias , 2012, Expert opinion on pharmacotherapy.

[13]  U. Dührsen,et al.  Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia , 2012, Leukemia.

[14]  R. Foà,et al.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[15]  R. Foà,et al.  Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis , 2011, Haematologica.

[16]  R. Pieters,et al.  Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.

[17]  S. Mustjoki,et al.  Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.

[18]  E. Thiel,et al.  Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. , 2008, Blood.

[19]  J. Downing,et al.  Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. , 2008, Genes & development.

[20]  V. Meignin,et al.  Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. , 2007, American journal of respiratory and critical care medicine.

[21]  U. Dührsen,et al.  Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) , 2007, Cancer.

[22]  R. Foà,et al.  Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged , 2007 .

[23]  H. Dombret,et al.  Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study , 2006, Leukemia.

[24]  H. Dombret,et al.  High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia , 2006, Leukemia.

[25]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[26]  A. Delannoy,et al.  Acute lymphoblastic leukemia in the elderly. , 2002, The hematology journal : the official journal of the European Haematology Association.

[27]  Odd Aalen,et al.  Nonparametric Estimation of Partial Transition Probabilities in Multiple Decrement Models , 1978 .